on VALBIOTIS (EPA:ALVAL)
Exclusive distribution agreement for Valbiotis in Qatar
Valbiotis, a French laboratory specializing in nutritional solutions, has signed an exclusive distribution agreement with Al Danah Medical Company in Qatar. This collaboration marks a new step in the brand's expansion in the Middle East. ValbiotisPRO® products, which target cardiometabolic imbalances, will soon be available on the Qatari market.
The agreement aims to leverage Al Danah Medical's local expertise to distribute and promote Valbiotis products to Qatari healthcare professionals. Commercialization is expected to begin after obtaining the necessary approvals, with initial revenues anticipated in 2027. This initiative is part of an ambitious international expansion strategy, already underway with partnerships in Asia and other Middle Eastern countries.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all VALBIOTIS news